Denosumab in Postmenopausal Women with Low Bone Mineral Density

R. McClung, Michael; Michael Lewiecki, E.; Cohen, Stanley; A. Bolognese, Michael; C. Woodson, Grattan; H. Moffett, Alfred; Peacock, Munro; D. Miller, Paul; Lederman, Samuel; H. Chesnut, Charles; Lain, Douglas; Kivitz, Alan; Holloway, Donna; Zhang, Charlie; Peterson, Mark; Bekker, Pirow

doi:10.1056/nejmoa044459

Public

Denosumab in Postmenopausal Women with Low Bone Mineral Density

Published in New England Journal of Medicine • Feb 22, 2006

Authors:

Michael R. McClung

E. Michael Lewiecki

Stanley Cohen

Abstract

BACKGROUND: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: T...

Subject

Denosumab

Medicine

Bone mineral

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!